Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy
Unknown statusPhase 1, Phase 2NCT02439541
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Phase I-II Clinical Trial-Safety and efficacy of umbilical cord derived mesenchymal stem cells (UC-MSCs) in patients with chronic heart ischemia cohort and perspective study.
Study details
- Official title
- Safety and Efficacy of Human Umbilical-Cord-derived Mesenchymal Stem Cell Transplantation in Ischemic Cardiomyopathy
- Conditions
- Chronic Ischemic Heart Disease
- Heart Failure
- Angina
- Interventions
- Biological: UCMSC group
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
- Collaborators
- Ivy Institute of Stem Cells Co. Ltd
- Start date
- 2015-05
- Primary completion
- 2017-12
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age between 18 and 80 y * No option for PCI or CABG (Angiographies evaluated by an independent interventional cardiologist). * Maximal tolerable angina and heart failure medication * NYHA functional classification (I-III) * Signed informed consent Exclusion Criteria: * Severe liver or renal dysfunction or hemorrhagic diseases not suitable for PCI. * Severe cerebral ischemic stroke or cerebral hemorrhage within 6 month. * History with malignant disease within 5 y of inclusion or suspected malignity * Severe heart failure (NYHA functional classification IV) * Diminished functional capacity for other reasons such as COPD, alcoholic cardiomyopathy, or viral myocarditis * Clinical significant anemia, leukopenia, leukocytosis,or thrombocythemia * Clinical significant abnormal prothrombin or partial thromboplastin time or anticoagulation treatment that cannot be paused during treatment * Patients with reduced immune response or treated with immunosuppressive medication * Combined with severe infectious diseases * Pregnant or fertile women * Socially and mentally disabilities
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02439541